Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24052556 | 0.91 | — | — | |
| SCHEMBL28175196 | 0.90 | — | — | |
| SCHEMBL24052553 | 0.87 | — | — | |
| SCHEMBL20913352 | 0.86 | TP53 (0.35) | — | |
| SCHEMBL16036398 | 0.85 | TP53 (0.33) | — | |
| SCHEMBL20913346 | 0.83 | — | — | |
| SCHEMBL20959564 | 0.82 | CCNT1 (0.30) | — | |
| SCHEMBL24267967 | 0.82 | — | — | |
| SCHEMBL20926949 | 0.81 | SYK (0.31) | — | |
| SCHEMBL16076736 | 0.81 | STK17B (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | G1 THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | NDC1, SDC1, SDC2 | HCAR1 939/4885 |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CDK2, CCNI, CCNK | HCAR1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.